NOVO'S OZEMPIC® (SEMAGLUTIDE) 2 MG ASSOCIATED WITH LOWER RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (DEATH, HEART ATTACK, AND STROKE) IN ADULTS WITH TYPE 2 DIABETES COMPARED TO SWITCHING TO MOUNJARO® (TIRZEPATIDE), IN REAL-WORLD ANALYSIS AT EASD 29-SEP-2026 06:00 AM ET